Home › Systolic Heart Failure › NCT07131631

Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1\. Adult patients (≥ 18 years old) with heart failure and reduced ejection fraction (LVEF \< 50% defined by echocardiography), medically and device-optimized according to guidelines, with significant FMR undergoing TEER with FDA-approved MitraClip device (Abbott Structural, USA)

Exclusion Criteria:

1. Concomitant PCI and TEER
2. Congenital heart disease
3. Stage D heart failure
4. Uncontrolled atrial fibrillation
5. Pregnancy
6. \> moderate tricuspid regurgitation
7. \>moderate aortic regurgitation or stenosis
8. Contraindications or unable to undergo CMR
9. Prior mitral valve repair or replacement

About the study

This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.

What is being tested

• Cardiac MRI (diagnostic test)

Sponsor: Minneapolis Heart Institute Foundation · Participants: 125 · Started: Mar 3, 2022

Contact the study team

• João Cavalcante, MD · Phone: 612-863-3900
• Sarah Schwager, RN · Phone: 612-863-6257

Official record on ClinicalTrials.gov — NCT07131631

Locations in the U.S.

Conditions

• Systolic Heart Failure
• Heart Failure

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.